A Japanese study demonstrated that patients with strong leg muscles have a lower risk of developing heart failure (HF) after acute myocardial infarction (AMI). This association remained significant even after adjusting for known cardiovascular risk factors.
Despite remarkable progress in treatment strategies in patients with AMI, the incidence of HF after AMI remains high. Therefore, the identification of predictive factors of the development of HF in patients with AMI is of key importance. A study presented by physiotherapist Mr Kensuke Ueno (Kitasato University Graduate School of Medical Sciences, Japan) explored whether muscle strength is an indicator of the development of HF. Included in the study were 932 participants hospitalised between 2007 to 2020 with AMI with no HF prior to admission and who did not develop HF complications during their hospital stay.
Maximal isometric quadriceps strength was assessed as an indicator of leg strength. Participants were asked to sit on a chair and contract the quadriceps muscles as hard as possible for 5 seconds. A handheld dynamometer attached to the ankle recorded the maximum value in kg. The measurement was performed on each leg and the average of both values was used. Strength was expressed relative to body weight. Patients were classified as ‘high’ or ‘low’ strength according to whether their value was above or below the median for their sex.
The identified median value for women was 33% of body weight and for men 52% of body weight. A total of 451 patients had low quadriceps strength and 481 had high strength. During an average follow-up of 4.5 years, 67 patients (7.2%) developed HF. The incidence of HF was 10.2 per 1,000 person-years in patients with high quadriceps strength and 22.9 per 1,000 person-years in those with low strength.
The cumulative incidence of HF events was significantly lower in the high-strength group than in the low-strength group (Plog-rank<0.001). After multivariate adjustment for known cardiovascular risk factors (i.e. age, sex, body mass index, prior myocardial infarction or angina pectoris, diabetes, atrial fibrillation, chronic obstructive pulmonary disease, peripheral arterial disease, and kidney function), high levels of quadriceps strengths were still associated with a lower risk of HF (HR 0.59; 95% CI 0.35–1.00; P=0.048). Moreover, each 5% body weight increment in quadriceps strength was associated with an 11% lower likelihood of HF (HR 0.89; 95% CI 0.81–0.98; P=0.014).
“Quadriceps strength is easy and simple to measure accurately in clinical practice. Our study indicated that quadriceps strength could help to identify patients at a higher risk of developing HF after myocardial infarction who could then receive more intense surveillance,” Mr Ueno concluded.
-
- Ueno K, et al. Leg strength and incidence of heart failure in patients with acute myocardial infarction, Session “moderated e-posters 3”. Heart Failure 2023, 20–23 May, Prague, Czechia.
Copyright ©2023 Medicom Medical Publishers
Posted on
« Coeliac Disease: “among the top 10 hard-to-diagnose common diseases” – an interview with Dr Cynthia Kelly Next Article
Protein-bound uremic toxins predict HF events and death in patients with chronic kidney disease »
Table of Contents: HFA 2023
Featured articles
Significant NT-proBNP reduction with sacubitril/valsartan in HF patients with ejection fraction >40%
Online First
DAPA MODA trial: Dapagliflozin improves multiple parameters of cardiac remodelling
A single nutritional intervention can reduce adverse outcomes in acute heart failure
Obese HF patients with type 2 diabetes at high risk to develop depression
Aficamten may lower symptom burden in non-obstructive hypertrophic cardiomyopathy
ENACT-HF: Standardised diuretic protocol improves natriuresis in acute heart failure
Significant NT-proBNP reduction with sacubitril/valsartan in HF patients with ejection fraction >40%
Protein-bound uremic toxins predict HF events and death in patients with chronic kidney disease
Stronger legs mean a lower risk of developing HF after AMI
AI-based technology successful in SARS-CoV-2 symptoms screening
NUDGE-FLU: Repeated electronic nudges improve flu vaccination rates in patients with HF
Haemodynamic monitoring improves quality of life and lowers hospitalisations in HF patients
Copper chelating agent improves biomarkers and quality of life in HF patients
Patisiran benefits maintained over 18 months in patients with transthyretin amyloidosis
Vascular Endothelial Growth Factor C: a novel potential biomarker for peripheral tissue congestion in acute heart failure
Obstructive sleep apnea: highly prevalent in patients with acute ischaemic stroke
Related Articles
Mobile stroke units improve stroke outcomes
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy